Market Cap : 41.4 B | Enterprise Value : 43.71 B | PE Ratio : 14.64 | PB Ratio : 3.24 |
---|
BIIB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BIIB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Biogen's Operating Income for the three months ended in Sep. 2022 was $825 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2022 was $2,959 Mil.
Operating Margin % is calculated as Operating Income divided by its Revenue. Biogen's Operating Income for the three months ended in Sep. 2022 was $825 Mil. Biogen's Revenue for the three months ended in Sep. 2022 was $2,509 Mil. Therefore, Biogen's Operating Margin % for the quarter that ended in Sep. 2022 was 32.88%.
Warning Sign:
Biogen Inc operating margin has been in a 5-year decline. The average rate of decline per year is -11.1%.
Biogen's 5-Year average Growth Rate for Operating Margin % was -11.10% per year.
Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Biogen's annualized ROC % for the quarter that ended in Sep. 2022 was 16.57%. Biogen's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2022 was 124.16%.
The historical data trend for Biogen's Operating Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.
Operating Income for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,959 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Biogen's annualized ROC % for the quarter that ended in Sep. 2022 is calculated as:
ROC % (Q: Sep. 2022 ) | ||||||
= | NOPAT | / | Average Invested Capital | |||
= | Operating Income * ( 1 - Tax Rate % ) | / | ( (Invested Capital (Q: Jun. 2022 ) | + | Invested Capital (Q: Sep. 2022 )) | / count ) |
= | 3298.8 * ( 1 - 17.23% ) | / | ( (16621.8 | + | 16330.2) | / 2 ) |
= | 2730.41676 | / | 16476 | |||
= | 16.57 % |
where
Invested Capital | (Q: Jun. 2022 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 25081.4 | - | 3736.7 | - | ( 4797.9 | - | max(0, 5018 | - | 9740.9 | + | 4797.9 | )) |
= | 16621.8 |
Invested Capital | (Q: Sep. 2022 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 24854.2 | - | 3612.9 | - | ( 4911.1 | - | max(0, 3926.4 | - | 9765.8 | + | 4911.1 | )) |
= | 16330.2 |
Note: The Operating Income data used here is four times the quarterly (Sep. 2022) data.
2. Joel Greenblatt's definition of Return on Capital:
Biogen's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2022 is calculated as:
ROC (Joel Greenblatt) % | (Q: Sep. 2022 ) | ||||||
= | EBIT | / | Average of (Net fixed Assets | + | Net Working Capital) | ||
= | EBIT | / | Average of (Property, Plant and Equipment | + | Net Working Capital) | ||
Q: Jun. 2022 | Q: Sep. 2022 | ||||||
= | EBIT | / | ( ( (Property, Plant and Equipment + Net Working Capital) | + | (Property, Plant and Equipment + Net Working Capital) ) | / | count ) |
= | 5724 | / | ( ( (3676.2 + max(924.8, 0)) | + | (3690.9 + max(928.3, 0)) ) | / | 2 ) |
= | 5724 | / | ( ( 4601 | + | 4619.2 ) | / | 2 ) |
= | 5724 | / | 4610.1 | ||||
= | 124.16 % |
where Working Capital is:
Working Capital | (Q: Jun. 2022 ) | ||||||||||
= | (Accounts Receivable | + | Total Inventories | + | Other Current Assets) | - | (Accounts Payable & Accrued Expense | + | Defer. Rev. | + | Other Current Liabilities) |
= | (2003.5 | + | 1294.2 | + | 1645.3) | - | (3736.7 | + | 0 | + | 281.5) |
= | 924.8 |
Working Capital | (Q: Sep. 2022 ) | ||||||||||
= | (Accounts Receivable | + | Total Inventories | + | Other Current Assets) | - | (Accounts Payable & Accrued Expense | + | Defer. Rev. | + | Other Current Liabilities) |
= | (1984.2 | + | 1375 | + | 1495.5) | - | (3612.9 | + | 0 | + | 313.5) |
= | 928.3 |
When net working capital is negative, 0 is used.
Note: The EBIT data used here is four times the quarterly (Sep. 2022) EBIT data.
3. Operating Income is also linked to Operating Margin %:
Biogen's Operating Margin % for the quarter that ended in Sep. 2022 is calculated as:
Operating Margin % | = | Operating Income (Q: Sep. 2022 ) | / | Revenue (Q: Sep. 2022 ) |
= | 824.7 | / | 2508.5 | |
= | 32.88 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.
Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Thank you for viewing the detailed overview of Biogen's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Christopher Viehbacher | director, officer: President and CEO | C/O AXCELLA HEALTH, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Nicole Murphy | officer: Head of Pharm Ops and Tech | BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142 |
Rachid Izzar | officer: Head of Alzheimer's Disease | BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142 |
Jones William D /ca/ | director | |
Maria C Freire | director | C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101 |
Michael R Mcdonnell | officer: EVP, Chief Financial Officer | C/O IQVIA HOLDINGS INC., 83 WOOSTER HEIGHTS ROAD, DANBURY CT 06810 |
Alphonse Galdes | officer: EVP Pharmaceutical Oper & Tech | BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142 |
William A Hawkins | director | MEDTRONIC INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604 |
Jesus B Mantas | director | BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142 |
Robin Kramer | officer: VP, Chief Accounting Officer | 999 VANDERBILT BEACH ROAD, 3RD FLOOR, NAPLES FL 34109 |
Daniel Karp | officer: EVP, Corporate Development | 225 BINNEY STREET, CAMBRIDGE MA 02142 |
Jeffrey D Capello | officer: EVP & Chief Financial Officer | C/O NEOGEN CORP., 620 LESHER PLACE, LANSING MI 48912 |
Chirfi Guindo | officer: EVP Glob. Mkt Acc & Cust Innov | C/O BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142 |
Ginger Gregory | officer: EVP, Human Resources | C/O BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142 |
Jean-paul Kress | officer: EVP Pres Int'l & Global Hd GTO | 215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142 |
From GuruFocus
By Value_Insider 10-26-2022
By PRNewswire 01-16-2023
By PRNewswire 11-30-2022
By Stock market mentor 01-27-2023
By PRNewswire 01-07-2023
By Value_Insider 11-28-2022
Other Sources
By Zacks 2023-01-30
By tipranks.com 2023-01-25
By Zacks 2023-01-27
By CNBC 2023-01-20
By Yahoo Finance 2023-01-25
By Yahoo Finance 2023-01-26
By Yahoo Finance 2023-01-20
By tipranks.com 2023-01-22
By Yahoo Finance 2023-01-26
By Yahoo Finance 2023-01-29
By Yahoo Finance 2023-01-25
By Zacks 2023-01-26
By Yahoo Finance 2023-01-30
By Yahoo Finance 2023-01-24
By Yahoo Finance 2023-01-29